Previous Article | Next Article 
Journal of Virology, November 1999, p. 8989-8998, Vol. 73, No. 11
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Adeno-Associated Virus Type 2 Protein Interactions:
Formation of Pre-Encapsidation Complexes
Ralf
Dubielzig,
Jason A.
King,
Stefan
Weger,
Andrea
Kern, and
Jürgen A.
Kleinschmidt*
Deutsches Krebsforschungszentrum, Forschungsschwerpunkt
Angewandte Tumorvirologie, D-69120 Heidelberg, Germany
Received 2 June 1999/Accepted 2 August 1999
 |
ABSTRACT |
The nonstructural adeno-associated virus type 2 Rep proteins are
known to control viral replication and thus provide the single-stranded DNA genomes required for packaging into preformed capsids. In addition,
complexes between Rep proteins and capsids have previously been
observed in the course of productive infections. Such complexes have
been interpreted as genome-linked Rep molecules associated with the
capsid upon successful DNA encapsidation. Here we demonstrate via
coimmunoprecipitation, cosedimentation, and yeast two-hybrid analyses
that the Rep-VP association also occurs in the absence of packageable
genomes, suggesting that such complexes could be involved in the
preparation of empty capsids for subsequent encapsidation steps. The
Rep domain responsible for the observed Rep-VP interactions is situated
within amino acids 322 to 482. In the presence of all Rep proteins,
Rep52 and, to a lesser extent, Rep78 are most abundantly recovered with
capsids, whereas Rep68 and Rep40 vary in association depending on their
expression levels. Rep78 and Rep52 are bound to capsids to roughly the
same extent as the minor capsid protein VP2. Complexes of Rep78 and
Rep52 with capsids differ in their respective detergent stabilities,
indicating that they result from different types of interactions.
Rep-VP interaction studies suggest that Rep proteins become stably
associated with the capsid during the assembly process. Rep-capsid
complexes can reach even higher complexity through additional Rep-Rep
interactions, which are particularly detergent labile.
Coimmunoprecipitation and yeast two-hybrid data demonstrate the
interaction of Rep78 with Rep68, of Rep68 with Rep52, and weak
interactions of Rep40 with Rep52 and Rep78. We propose that the large
complexes arising from these interactions represent intermediates in
the DNA packaging pathway.
 |
INTRODUCTION |
Adeno-associated virus type 2 (AAV-2) is a human parvovirus dependent on coinfection with a helper
virus, such as adenovirus or herpesvirus, for efficient reproduction
(for reviews, see references 2, 3, and
28). The 4.7-kb single-stranded DNA (ssDNA) genome
is encapsidated in an icosahedral virion 20 to 24 nm in diameter. The
genome consists of two open reading frames (ORFs) flanked by inverted
terminal repeats (ITRs) of 145 nucleotides. The right ORF encodes the
three capsid proteins VP1, VP2, and VP3, which are translated from
alternative translation start sites and have molecular masses of 87, 72, and 62 kDa, respectively. The capsid proteins are present in the
mature virion in a 1:1:10 ratio (4, 33). Capsid assembly
occurs in the nucleus and requires only the expression of the capsid
proteins (34, 45). In the absence of Rep proteins, capsids
accumulate predominantly in the nuceoli (45). Encapsidation
of the ssDNA takes place in the nucleoplasm. Immunofluorescence data
indicate that the capsid proteins and the nonstructural Rep proteins
colocalize in certain areas of the nucleus (18, 45) and that
the Rep proteins are able to influence the subnuclear capsid
distribution (45). Coimmunoprecipitation experiments have
shown that Rep and capsid proteins can form complexes (31,
46). These complexes are at least partially stabilized by
covalent linkage of Rep78 to single-stranded AAV-2 DNA in the virion
(32), in analogy to findings for the autonomous parvovirus
minute virus of mice (MVM) (8).
The left ORF encodes the four nonstructural Rep proteins, with
molecular masses of 78, 68, 52, and 40 kDa, respectively. The two large
Rep proteins are required for AAV-2 DNA replication (14, 40)
and influence AAV-2 gene expression (1, 17, 24, 30, 41, 42).
They have ATP-dependent helicase and endonuclease activities (19,
21). The two small Rep proteins strongly stimulate ssDNA
accumulation (6), which may suggest a role in ssDNA
encapsidation. In principle, Rep78 and Rep68 are sufficient for the
production of infectious virions (15); however, coexpression
of Rep52 and Rep40 increases the infectious titer by up to 1,000-fold.
Recent experiments also revealed an ATP-dependent helicase activity
associated with Rep52 (37).
The two ITRs of the AAV genome serve as origins of AAV DNA replication
and are necessary and sufficient for packaging (26, 35). A
specific packaging sequence within the ITR has so far not been
identified. In vivo pulse-labeling experiments have shown that the
number of empty particles decreases at the same rate as the number of
DNA-containing mature virions increases over the course of a viral
infection (29). Interpretation of these data led to the
hypothesis that ssDNA is packaged into preformed empty capsids. This
model is supported by findings relating to autonomous parvoviruses for
which capsids with attached DNA as potential packaging intermediates
have been visualized by electron microscopy (27). Recently,
infectious AAV-2 has been produced in cell-free systems which might
help to analyze the mechanism of DNA encapsidation in more detail
(9, 47).
Encapsidation of the DNA is a crucial step in the production of
wild-type and recombinant AAV-2. In both cases, the number of empty
capsids exceeds the number of packaged infectious virions. The
underlying mechanisms both of capsid assembly and DNA packaging are not
yet understood. In particular, there is no explanation for the apparent
specificity of the AAV-2 DNA packaging process. Here we describe
complexes between Rep proteins and capsids as well as between different
Rep proteins which provide a molecular basis for the specific
association of AAV-2 DNA with preformed capsids prior to encapsidation.
A model describing the formation of the initial encapsidation complexes
is presented.
 |
MATERIALS AND METHODS |
Materials.
The polyclonal guinea pig Rep antisera
Rep-S,
Rep-M, and
Rep-A against the Rep proteins derived from spliced
mRNAs (Rep68 and Rep40) and against all Rep proteins, respectively, and
the monoclonal antibodies (MAbs) 303.9 (directed against the Rep
proteins) and B1 (directed against the capsid proteins) have been
described previously (42, 46). A polyclonal guinea pig
antiserum (
Rep-US) specifically reacting with the Rep proteins
derived from the nonspliced mRNAs (Rep78 and Rep52) was generated by
immunization of guinea pigs with the peptide GKVPDACTACDLVNVDLDDCIFEQ
according to conventional protocols (12). The rabbit
polyclonal antisera 48, 51, and 87, reacting with the VP proteins, were
prepared after immunization by using the VP1 capsid protein which was
expressed in a baculovirus system and then gel purified.
The expression vectors pRep, including Rep78, Rep68, Rep52, Rep40,
M225, M274, M324, Stop482, Stop515, and RepK340H are identical to the
corresponding pKEXRep constructs previously described (17). The mutant Rep52
XS was generated via deletion of the
XmnI-SalI region of Rep52. Through blunting of
the SalI site and ligation to the blunt XmnI end,
the original Rep reading frame was conserved. Constructs containing
point mutations (E379K, E379Q, E391I, E391T, K404I, K404T, and P415H)
in the Rep helicase domain have been previously described
(25) and were kindly provided by N. Muzyczka. SalI-SwaI fragments were removed from these
Rep/Cap expression constructs and inserted into a cytomegalovirus
(CMV)-Rep52/40 expression construct (pRepM225). pDG
VP was prepared
by homologous recombination. For this, a 1.1-kb ApaI
fragment which comprises nucleotides 2946 to 4049 of the VP ORF was
deleted from p
TR (42), resulting in plasmid p
TR
VP.
The 1.8-kb XbaI/HindIII fragment from
p
TR
VP was then cotransformed with pDG (11) linearized with SwaI into Escherichia coli BJ5183 for
homologous recombination (5).
For quantitation of the sensitivity of MAbs 303.9 and B1, Rep68 and VP3
were expressed and purified as described earlier (
16,
38).
Cell culture, virus infection, and plasmid transfection.
293T cells were maintained in Dulbecco's modified Eagle's medium
(DMEM) supplemented with 10% heat-inactivated fetal calf serum and 100 µg/ml of penicillin and streptomycin at 37°C in 5%
CO2. Cells were coinfected with AAV-2 and adenovirus type 5 (Ad5) at 80% confluency. The medium was removed, and the cells were
then incubated with AAV-2 (multiplicity of infection [MOI] of 20) and
Ad5 (MOI of 2) in a total volume of 500 µl per 6-cm-diameter petri
dish for 2 h. DMEM was added, and the cells were incubated at
37°C in 5% CO2 for 72 h.
Cells were transfected as described elsewhere (
7). 293T
cells at approximately 60% confluency were transfected with 10
µg of
plasmid DNA per 6-cm petri
dish.
Preparation of cell extracts.
The cells were harvested at
72 h postinfection or posttransfection and washed with 5 ml of
phosphate-buffered saline (PBS) and then with 1 ml of PBS per dish.
Cells from a 6-cm dish were resuspended in a final volume of 0.5 ml or
in 1 ml of buffer A (10 mM Tris-Cl, pH 7.5, 100 mM NaCl, 1 mM EDTA) or
RIPA buffer (10 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Nonidet
P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS]). To both buffers the complete proteinase inhibitor cocktail (Roche, Mannheim, Germany) was added as suggested by the manufacturer. The cell
suspensions in buffer A were sonicated twice for 15 s. All
extracts were cleared by centrifugation at an average of
17,600 × g for 5 min (4°C).
Sucrose gradients.
Nuclear extracts of 293T cells
transfected with pDG from 10 10-cm petri dishes were prepared as
previously described (46). Samples of 0.5 ml were loaded
onto 10-ml sucrose gradients (5 to 30% sucrose in TNEM buffer [10 mM
Tris-Cl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 2 mM MgCl2, 5 mM
-mercaptoethanol]) and centrifuged for 2 h at
160,000 × g at 4°C in a swing-out rotor. Fractions of 1 ml were collected from the bottoms of the tubes. Rep and VP
concentrations were controlled by precipitation in trichloroacetic acid
(final concentration of 20%) of 200 µl of the fractions, followed by
SDS-polyacrylamide gel electrophoresis (PAGE) and Western blot
analysis. The remaining 800 µl of the fractions was used for
immunoprecipitation experiments.
Western blot analysis.
Protein samples were electrophoresed
on 15% polyacrylamide gels in the presence of SDS (39) and
transferred to nitrocellulose membranes using semidry blotting
equipment. The Rep and capsid proteins were detected with MAbs and
peroxidase-coupled secondary antibodies using the enhanced
chemoluminescence (ECL) detection kit (Amersham, Braunschweig, Germany)
according to standard methods (12).
Immunoprecipitation experiments.
Three hundred to 500 µl
of cell extract or 800 µl of sucrose gradient fractions was incubated
overnight at 4°C with either 3 µl of polyclonal guinea pig
antiserum or polyclonal rabbit antiserum. After this incubation, the
samples were cleared of nonspecific protein precipitates by
centrifugation at 17,600 × g for 5 min. The
immunocomplexes were precipitated via the addition of 30 µl of
protein A-Sepharose (Amersham-Pharmacia, Freiburg, Germany) (10%
[wt/vol] in NETN [20 mM Tris-Cl, pH 7.5, 100 mM NaCl, 1 mM EDTA,
0.5% Nonidet P-40]). After overnight incubation at 4°C, the
immunocomplex-protein A-Sepharose beads were washed three times with 1 ml of NETN buffer in which guinea pig antisera had been used.
Immunoprecipitations carried out using rabbit antisera in RIPA buffer
or buffer A were washed three times with 1 ml of the respective lysis
buffer instead of NETN. The samples were boiled in protein loading
buffer and analyzed by SDS-PAGE and Western blotting.
Two-hybrid vectors and interaction assay.
The Rep two-hybrid
constructs were cloned as follows. Plasmids pGBT9 and pGAD424 (Clontech
Laboratories, Inc., Palo Alto, Calif.) encoding the GAL4 DNA-binding
and the GAL4 transactivation domain, respectively, were cut with
SalI and PstI and ligated to a
SalI/PstI fragment from HIV-LTR-OVEC
(16) containing the EcoRV site derived from
pBluescript SK2 adjacent to the PstI site. The resulting
plasmids were digested with SalI and partially with EcoRV to excise only the HIV-LTR-derived inserts. The vector
fragments were ligated to Rep78- and Rep52-encoding
XhoI/SmaI fragments from pRep78 and pRep52,
respectively, to obtain pGBT9-Rep78, pGBT-Rep52, pGAD424-Rep78, and
pGAD424-Rep52. To generate the Rep68- and Rep40-encoding two-hybrid
constructs, the NotI/XbaI-Rep78 fragments of
pGBT9-Rep78 and pGAD424-Rep78, respectively, were replaced by the
corresponding fragments from pRep68 and pRep40. The vector for the
expression of the AAV-2 VP proteins in fusion with the yeast GAL4
activation domain (pGAD-VP) was generated by inserting the
DraI/SnaBI fragment of pTAV2-0 into the blunted
BamHI site of pGAD424. The corresponding pGBT-VP construct
containing the AAV-2 cap gene fused to the gene for the
yeast GAL4-binding domain was prepared by ligating the VP-containing
EcoRI/SalI fragment of pGAD-VP into pGBT9 that
had been digested with EcoRI and SalI.
The constructs were transformed according to a basic lithium acetate
protocol (
10) in every possible pairwise combination
into
Saccharomyces cerevisiae PJ69-4 (
22), which
contains three
reporter genes,
ADE2,
HIS3, and
lacZ, under the control of three
independent promoters,
Gal2, Gal1, and Gal7. The resulting 36
double transformants were
selected on synthetic complete medium
lacking leucine and
tryptophan.
For the in vivo assays, fresh transformants were streaked onto
tryptophan- and leucine-deficient medium lacking adenine or
histidine
or supplemented with a final concentration of 100 mM
sodium phosphate
(pH 7.0) and 40 µg of X-Gal
(5-bromo-4-chloro-3-indolyl-

-
D-galactopyranoside)
per
ml, respectively, and incubated for 72 h at 30°C.
Cotransformants
displaying a positive reaction on at least one of the
selective
media were subjected to a liquid culture assay by
quantitative
colorimetric measurement of

-galactosidase activity
using chlorophenol
red

-
D-galactopyranoside (CPRG)
(
36). The liquid culture assay
was performed at least twice
with three independent cotransformants
and triple
measurements.
 |
RESULTS |
Complex formation between Rep and VP proteins in the absence of
packageable DNA.
In the course of a productive AAV-2 infection,
complexes between Rep and capsid proteins (VP proteins) can be
demonstrated by coimmunoprecipitation with antibodies against the Rep
proteins (31, 46). These complexes have been interpreted as
being the result of ssDNA packaging in which Rep is covalently linked
to the viral DNA and thereby indirectly associated with the capsid (31, 32). To determine whether the association of Rep
proteins with capsid proteins or capsids requires AAV-2 DNA, Rep-VP
complex formation was studied following transfection of Rep and VP
protein expression constructs in the presence and absence of
replicatable and packageable DNA. 293T cells were cotransfected either
with the AAV-2 vector plasmid pUF2 (Fig.
1) (48) and the helper plasmid pDG (Fig. 1) (11), which provides AAV-2 and all adenovirus
helper functions, or with pBluescript SK+ (pBS), a plasmid which can neither be replicated nor packaged into AAV-2 capsids, and the pDG
helper plasmid. As a positive control, 293T cells were infected with
AAV-2 (MOI, 20) and Ad5 (MOI, 2) or transfected with pTAV2-0 (Fig. 1),
an infectious AAV-2 clone, and infected with Ad5 (MOI, 2). The Rep
proteins were immunoprecipitated from extracts of cells harvested
72 h postinfection or posttransfection with polyclonal guinea pig
antisera recognizing all four Rep proteins (
Rep-A or
Rep-M).
Coprecipitated capsid proteins were detected by SDS-PAGE and Western
blot analysis by using the monoclonal antibody B1 (45). It
is evident from Fig. 2a that capsid
proteins can be coprecipitated with the Rep proteins to the same extent
following transfection of the pTAV2-0 infectious clone as after
infection. In addition, coimmunoprecipitation of VP proteins occurred
not only in the presence of replication- and packaging-competent DNA (pUF2) but also in the presence of replication- and packaging-deficient DNA (pBS) (Fig. 2b). Control precipitations with an unrelated guinea
pig antiserum showed no precipitation of capsid proteins. To further
validate these results, coimmunoprecipitations using two additional
polyclonal antisera were performed from extracts of cells transfected
with pDG alone. The specificities of the various guinea pig antisera
were demonstrated by Western blot analysis (Fig. 2c). Whereas the
Rep-S antiserum reacts only with Rep40 and Rep68 (see also reference
42),
Rep-US specifically detects Rep78 and Rep52
in Western blot analysis. Both
Rep-S and
Rep-US coprecipitated
the capsid proteins, indicating that Rep proteins derived from spliced
and unspliced mRNA form complexes with the VP proteins (Fig. 2d). In
addition, this result confirms that packageable DNA is not required for
Rep-VP complex formation.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 1.
Diagrams of (a) packageable AAV plasmids, (b) expression
constructs containing the rep and cap genes under
control of the CMV immediate-early promoter, and (c) helper plasmids
providing AAV-2 and all adenovirus helper functions. (a) pTAV2-0
(13) contains the complete AAV-2 genome coding for the Rep
proteins (Rep) and the capsid proteins (VP); pUF2 (48) is a
recombinant AAV-2 plasmid and contains the gene for a green fluorescent
protein (gfp) under control of the CMV promoter and the
neomycin-resistance gene (neo) under control of the herpes simplex
virus thymidine kinase promoter. (b) pRep contains the respective
rep genes shown in Fig. 3 and described in Materials and
Methods. pCMV-VP (45) contains the complete VP gene and
allows the expression of all three capsid proteins in the correct
stoichiometry, whereas pKEX-VP1, pKEX-VP2, and pKEX-VP3 (34)
harbor point mutations allowing expression of the individual VP
proteins. (c) pDG (11) contains the Rep and VP expression
cassette of AAV-2. The p5 promoter was exchanged for the mouse mammary
tumor virus (MMTV) promoter. The adenovirus genes necessary for AAV
production are indicated by black boxes. TR, Ad5 terminal repeat; VA,
virus-associated genes I and II; E2A and E4, early region 2A and 4 of
Ad5. pDG VP contains a deletion within the coding region for the
capsid proteins (VP ). Both pDG and pDG VP lack the AAV-2 ITRs.
|
|

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 2.
Coimmunoprecipitation of VP proteins with anti-Rep
antisera in the presence and absence of AAV-2 DNA packaging. Extracts
of 293T cells were prepared as described in Materials and Methods using
RIPA buffer after coinfection with AAV-2 (AAV) and Ad5 or after
transfection with pTAV2-0 and infection with Ad5 (a), after
cotransfection with pDG and pBluescript SK+ (pBS) or pUF2, respectively
(b), or after transfection with pDG (c and d). Immunoprecipitation was
accomplished by incubating the extracts with a guinea pig anti-Rep
polyclonal antiserum ( Rep-A) or an unrelated guinea pig polyclonal
antiserum (Control) (a and b) or guinea pig polyclonal antisera which
recognize Rep78 and Rep52 ( Rep-US) or Rep68 and Rep40 ( Rep-S),
respectively (d). The immunoprecipitates were analyzed by Western
blotting using the anti-VP MAb B1 (46) and ECL detection.
IgG, position of the IgG heavy chain fraction precipitated with protein
A-Sepharose and detected by the peroxidase-coupled anti-mouse secondary
antibody. M, marker extract derived from HeLa cells coinfected with
AAV-2 and Ad5. (c) Western blot analysis with the different Rep
antisera used for immunoprecipitation compared to MAb 303.9 (46).
|
|
Mapping of the VP interaction domain of the Rep proteins.
The
ability of individual Rep proteins and Rep protein mutants to form
complexes with VP proteins was tested by cotransfecting increasing
amounts of the pCMV-VP expression construct (2, 4, or 8 µg) (Fig. 1)
with fixed amounts of various Rep expression constructs (2 µg) (Fig.
1). The Rep ORF depicted in Fig. 1b is representative of the individual
Rep proteins and Rep protein mutants shown in Fig.
3a. Rep and VP protein expression was
controlled by Western analysis, and Rep-VP complex formation was
analyzed by immunoprecipitation with
Rep-A or
Rep-M antiserum and
Western blot analysis as described above. Figures 3b and c show
examples of strong, weak, and noninteracting Rep proteins. All four Rep proteins showed a detectable interaction with VP proteins in this assay. Larger amounts of VP proteins were coprecipitated using the
small Rep proteins than with the large Rep proteins. C- and N-terminal
deletions as well as point mutations in the ATP-binding site of the Rep
proteins and in proline 415 further reduced the interaction with the
capsid proteins. An internal deletion between amino acids 322 and 370 (Rep52
XS) showed no detectable VP coprecipitation (Fig. 3b and c).
This mutant turned out to be less soluble within the cell and therefore
could only be tested at a reduced expression level. We concluded from
these results that each of the Rep proteins is able to form complexes
with the capsid proteins and that the most important interaction
site(s) is contained within the domain spanning amino acids 322 to 482.


View larger version (91K):
[in this window]
[in a new window]
|
FIG. 3.
Mapping of the Rep protein domain critical for Rep-VP
interactions. Extracts of 293T cells transfected with a fixed amount of
either Rep expression plasmid (indicated in panel a) (2 µg/6-cm petri
dish) and increasing concentrations of pCMV-VP (2, 4, or 8 µg/6-cm
petri dish) were prepared in RIPA buffer and subjected to
immunoprecipitation with the Rep-A or Rep-M polyclonal antiserum
or an unrelated guinea pig antiserum (control) as described in
Materials and Methods. Controls also included immunoprecipitation from
cell extracts after cotransfection of the empty Rep expression vector
(pKEX) and increasing amounts of pCMV-VP with the Rep antiserum or
with the unrelated guinea pig antiserum. Detection of the VP proteins
was accomplished as described in the legend to Fig. 2. For
comparability, expression of the Rep and VP proteins was controlled in
the extracts before immunoprecipitation. (a) Compilation of VP proteins
coprecipitated with a number of Rep mutants. The amount of
coprecipitated capsid proteins is given on a semiquantitative scale
between +++ and . (b) Rep and VP expression controls of the examples
underlined in panel a. (c) The corresponding capsid proteins
coprecipitated with the Rep-M serum or the control serum.
M2251, constructs expressing small Rep proteins with
mutations at K391T or K404T; M2252, small Rep proteins with
mutations at E379K, E379Q, K391I, or K404I.
|
|
Characterization of Rep-VP complexes.
Since Rep-VP complex
formation was not restricted to a subset of the four Rep proteins, the
Rep content of the Rep-VP complexes was analyzed. Extracts of 293T
cells that had been infected with AAV-2 (MOI, 20) and Ad5 (MOI, 2) were
immunoprecipitated in the presence of RIPA buffer by using either a
polyclonal VP antiserum (
VP#87) or the preimmune serum. The
precipitates thus obtained were analyzed using a MAb (303.9) that
reacts with all four Rep proteins. It becomes obvious from Fig.
4a
that Rep52 was overrepresented in the precipitate, whereas Rep78 and
Rep68 were present in lower amounts, although comparison with total Rep
protein concentration present in the cell extract (Fig. 4a, extract
lanes) shows that Rep78 and Rep68 were abundantly expressed. Rep40 was
generally not detected in the immunoprecipitates except in low amounts
in experiments in which Rep40 was more highly expressed. The same result was obtained from immunoprecipitations using two other anti-VP
polyclonal rabbit antisera (#48 and #51) or after transfection of 293T
cells with pTAV2-0 and overinfection with Ad5 (MOI, 5) (data not
shown). No Rep proteins were detected following immunoprecipitation with the preimmune serum (control lanes). Immunoprecipitations shown so
far were performed using RIPA cell extracts that contain considerable
amounts of detergents. In order to analyze the composition of Rep-VP
complexes under less stringent conditions, cell extracts prepared using
detergent-free buffer A were used for immunoprecipitation with the VP
antiserum (
VP#87). Figure 4b shows that under these conditions,
considerably more Rep78 was recovered in the immunoprecipitate (lane
VP) than in the precipitation in RIPA buffer compared to the
expression level of the Rep proteins in the cell extract (extract lane). However, such precipitations always showed a higher background with the preimmune serum (control lane).

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 4.
Rep content of Rep-VP complexes in the presence and
absence of packageable DNA and in the presence and absence of
detergents. Extracts were prepared from 293T cells after coinfection
with AAV-2 and Ad5 (a and b), after transfection of pDG or pDG VP (5 µg/6-cm petri dish) (c), or after transfection of pDG or pDG VP (15 µg/10-cm petri dish, 10 petri dishes each) (d). They were subjected
to immunoprecipitation with a VP antiserum (VP#87; VP) in RIPA
buffer (a and c) or in buffer A (b). The precipitations in panel d were
performed in buffer A using a Rep antiserum ( Rep-M
[44]) after fractionation of nuclear extracts by
sucrose gradient centrifugation. The immunoprecipitates were analyzed
by SDS-PAGE and Western blotting using the 303.9 anti-Rep MAb or the B1
anti-VP antibody. Five microliters of the extract was directly
immunoblotted to determine the relative concentration of the Rep
proteins present in the extract (Extr. in panels a, b, and c). M,
marker extract derived from HeLa cells coinfected with AAV-2 and Ad5.
IgG, position of the rabbit IgG immunoprecipitated with protein
A-Sepharose cross-reacting with the peroxidase-coupled anti-mouse
secondary antibody. Control, immunoprecipitations with the preimmune
serum.
|
|
The Rep content of Rep-VP complexes in the absence of packageable DNA
was analyzed by immunoprecipitation of the VP proteins
in RIPA buffer
from extracts of 293T cells transfected either
with pDG or pDG

VP.
The pattern of Rep coprecipitation was similar
to that obtained
following infection of 293T cells with AAV-2
and Ad5 (Fig.
4c,

VP).
Rep52 was present in higher amounts than
Rep78, although the relative
amount of Rep78 in the cell extract
was almost equal to that of Rep52
(compare extract and

VP lanes).
Rep68 and Rep40 were neither
detected in the extract nor in the
immunoprecipitate. In the
immunoprecipitate obtained from 293T
cells transfected with pDG

VP
(Fig.
1) in which the
cap gene was
deleted, no Rep proteins
could be detected (Fig.
4c), demonstrating
the specificity of the
immunoprecipitates. In addition, control
precipitations with the
preimmune serum did not coprecipitate
significant amounts of Rep
proteins. The broad faint band at the
position of Rep52 represents the
immunoglobulin G (IgG) heavy
chain fraction of the antiserum weakly
detected by the anti-mouse
secondary antibody used in the Western blot
analysis.
The composition of the Rep-VP complexes formed in the absence of
packageable AAV-2 DNA was also analyzed by cosedimentation
of Rep
proteins with capsids at 60S. In these experiments, nuclear
extracts of
cells transfected with pDG or pDG

VP were fractionated
by sucrose
gradient centrifugation and subjected to Western blotting
using VP
antibodies (B1) or Rep antibodies (303.9). In some experiments,
the Rep
and VP proteins were concentrated by immunoprecipitation
with anti-Rep
antibodies prior to Western blot analysis (Fig.
4d); however, similar
results were obtained without this concentration
step (data not shown).
It is evident that Rep78 and Rep52 show
a peak in the capsid-containing
fractions around 60S which does
not appear in the absence of capsids
(Fig.
4d, lanes pDG

VP).
This result was obtained in a detergent-free
buffer system. It
also shows that the DNA-free complexes contain
predominantly Rep78
and Rep52 (at slightly higher levels). The
repeatedly observed
protein band that migrates slightly below Rep40 may
represent
a modified form of Rep40 or a degradation product of one of
the
four Rep proteins. The quantitation of the Rep and VP proteins
in
the 60S fractions from two representative sucrose gradients
suggests
that the Rep proteins are present in the 60S complexes
in amounts
comparable to or slightly higher than VP2 (Table
1).
Association of Rep proteins with free and assembled capsid
proteins.
In order to determine whether the Rep-VP interaction
occurs prior or subsequent to capsid assembly, the interactions of Rep proteins with nonassembled capsid proteins were analyzed. Nuclear extracts of pDG-transfected 293T cells were subjected to sucrose gradient centrifugation, and the resulting fractions were used in
coimmunoprecipitation experiments. Using the
Rep-A antiserum, capsid
proteins were predominantly coprecipitated from fractions containing
the fully assembled capsids, around 60S (Fig.
5a). However, some capsid proteins were
also specifically coprecipitated in fractions corresponding to S values
of less than 20S, suggesting that Rep proteins are not only associated
with the assembled capsids but also with nonassembled VP proteins. To
confirm the association of Rep proteins with free capsid proteins,
coimmunoprecipitation experiments were performed via cotransfection of
293T with the various Rep expression constructs (pRep40, pRep52,
pRep68, or pRep78) and constructs from which the individual capsid
proteins VP1, VP2, or VP3 (Fig. 1, pKEX-VP1, pKEX-VP2, and pKEX-VP3)
are expressed (34), but they show very poor or, in the case
of VP3, no capsid assembly (38). To monitor Rep association
with capsids, the three capsid proteins were coexpressed from
plasmid pCMV-VP (45). Using the
Rep-A antiserum,
only small amounts of the separately expressed VP3 or VP2 and no VP1
could be detected, whereas the assembled capsids (lane VP) in the
control experiment were abundantly recovered (Fig. 5c and d; only the
experiment with pRep40 is shown; similar results were obtained for the
other Rep proteins). These results demonstrate that VP3 and probably also VP2 are able to interact with the Rep proteins also in their nonassembled states. The specificity of these precipitations is shown
by the two controls (Fig. 5c, lane pKEX/VP, and 5d). The relatively
weak VP signals obtained following coprecipitation of individual VP
proteins with the Rep proteins can be explained by the small amount of
VP molecules present in these complexes, compared to complexes
involving capsids. Finally, data from two-hybrid interaction assays
also suggest that Rep78 and Rep52 can interact with nonassembled VP
proteins (see Fig. 8D and E). Such interactions were not observed in
this assay for the other Rep proteins.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 5.
Association of Rep proteins with free and assembled
capsid proteins. (a and b) Sucrose gradient fractions obtained from
nuclear extracts of 293T cells transfected with pDG (10 10-cm petri
dishes; 15 µg of pDG each) were subjected to immunoprecipitation with
the Rep-A or control polyclonal antisera in RIPA buffer as described
in Materials and Methods. The positions of 60S and 20S were determined
by using empty AAV-2 capsids (60S) and -macroglobulin (20S) in
parallel gradients. (c and d) 293T cells were cotransfected with the
expression constructs pRep40 (4 µg/6-cm petri dish) and pCMV-VP (VP),
pKEX-VP3 (VP3), pKEX-VP2 (VP2), and pKEX-VP1 (VP1) (2 or 6 µg/6-cm
petri dish) or with the empty vector pKEX (4 µg/6-cm petri dish) and
pCMV-VP (VP) (6 µg/6-cm petri dish). Whole cell extracts were
immunoprecipitated with the Rep-A and control antisera in RIPA
buffer as described in Materials and Methods. VP proteins were detected
by Western blotting using MAb B1 and ECL. M, marker extract derived
from HeLa cells coinfected with AAV-2 and Ad5. IgG, position of guinea
pig IgG immunoprecipitated with protein A-Sepharose cross-reacting with
the peroxidase-coupled anti-mouse secondary antibody.
|
|
From the data so far obtained, Rep-capsid complexes could either be
formed by the association of Rep proteins with assembled
capsids or
with VP proteins during the assembly process. To distinguish
between
the two mechanisms, we compared Rep-capsid complexes obtained
by
coexpression of Rep and capsid proteins with complexes obtained
upon
separate expression and coincubation of the extracts in vitro.
Very
little capsid assembly occurs in vitro (
38), so that any
resulting interactions of Rep proteins with capsids or VP proteins
can
be said to be assembly independent. Whereas coexpression of
Rep40 with
the VP proteins led to the formation of a stable complex,
no VP
proteins were coprecipitated with Rep40 when the Rep and
VP proteins
were separately expressed and then mixed in vitro
(Fig.
6). Similar results were obtained using
Rep52 (data not
shown). This result also emphasizes that the abundance
of the
capsid proteins in the cell extract does not lead to a
nonspecific
coprecipitation with the Rep proteins.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 6.
Immunoprecipitation of Rep-VP complexes after Rep-VP
coexpression or separate expression of Rep and VP proteins and
subsequent mixing of extracts. Extracts from 293T cells cotransfected
(Co) or separately transfected with pRep40 and pCMV-VP were prepared in
RIPA buffer. The extracts of the separately transfected cells were
combined (Mix), and all extracts (with equal capsid and Rep protein
concentrations) were subjected to immunoprecipitation with the Rep-A
and control antisera. The precipitated proteins were analyzed by
Western blotting using the antibody B1 for detection of the VP proteins
as described in the legend to Fig. 2. M, marker extract derived from
HeLa cells coinfected with AAV-2 and Ad5.
|
|
Taken together, these data suggest that complex formation involving the
VP and Rep proteins occurs during capsid assembly
and results in the
formation of stable Rep-capsid complexes that
cannot be formed by
mixing cellular extracts in
vitro.
Rep-Rep complex formation.
Since all Rep proteins are able to
form complexes with VP proteins, we were interested in determining
whether Rep-Rep protein interactions could contribute to a
capsid-associated Rep protein complex possibly involved in AAV-2 DNA
packaging. Rep-Rep protein interactions were investigated by
coimmunoprecipitation and two-hybrid analyses.
The individual Rep proteins were either expressed separately or in
combination via cotransfection and immunoprecipitated using

Rep-S or

Rep-US polyclonal antisera. Extracts were prepared
in buffer A,
because the detergents present in RIPA buffer destabilize
Rep-Rep
interactions. The immunoprecipitated proteins were visualized
by
Western blot analysis. Small amounts of Rep52 and Rep78 could
be
coimmunoprecipitated with Rep40 (Fig.
7).
With Rep68, however,
Rep78 was coprecipitated in a 1:1 ratio. An
interaction between
Rep68 and Rep52 was difficult to detect using

Rep-S, since a
polypeptide of about the same molecular weight as
Rep52, which
also reacted with the 303.9 antibody, was precipitated
after expression
of Rep68 alone (Fig.
7,

Rep-S, lane 68). This
protein most likely
represents a degradation product of Rep68 that was
still recognized
by the

Rep-S serum. Immunoprecipitation using the

Rep-US antiserum,
however, showed a clear coprecipitation of Rep68
with Rep52 as
well as with Rep78, confirming and specifying a
previously observed
interaction of Rep52 with one of the large Rep
proteins (
30).
In contrast to the experiment with

Rep-S,
the weak interactions
of Rep40 with Rep52 and Rep78 could not be
detected.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 7.
Rep-Rep interactions in the presence and absence of DNA
replication. Extracts from 293T cells that had been transfected with
pRep40, pRep52, pRep68, or pRep78 or cotransfected with the different
Rep expression vectors in various combinations, as indicated, were
prepared and subjected to immunoprecipitation in buffer A with
Rep-S, Rep-US, or control antiserum as described in Materials and
Methods. Precipitated Rep proteins were detected by Western blotting
using MAb 303.9. M, marker extract derived from HeLa cells coinfected
with AAV-2 and Ad5. IgG, position of guinea pig IgG immunoprecipitated
with protein A-Sepharose cross-reacting with the peroxidase-coupled
anti-mouse secondary antibody.
|
|
In the two-hybrid system, the Rep as well as the VP proteins were fused
to the GAL4 activation (pGAD424) or binding (pGBT9)
domains,
respectively and cotransformed into the yeast strain
PJ69-4 in every
possible pairwise combination. The cotransformants
were analyzed for
the expression of three reporter genes under
the control of the GAL4
activatable promoters Gal1, Gal2, and
Gal7, respectively.
Cotransformants able to activate the least
stringent promoter (Gal7)
were subjected to a quantitative

-galactosidase
liquid culture
assay. The

-galactosidase activities are indicated
as Miller units
(Fig.
8). Rep52 and Rep78 showed a
background
activation of all three promoters when fused to the GAL4
DNA-binding
domain. Based on these assays, clear interactions could be
demonstrated
for Rep52 and Rep68 as well as for Rep68 and Rep78 fused
to either
of the GAL4 domains (Fig.
8B and C), thus supporting the
results
from the coimmunoprecipitation experiments. Rep52 and Rep40
showed
a slight activation of the Gal7 promoter only when Rep40 was
fused
to the GAL4 activation domain (Fig.
8A).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 8.
Rep-Rep and Rep-VP interactions detected in the yeast
two-hybrid system. The Rep and VP proteins were fused to the GAL4
activation domain and GAL4-binding domain, respectively, as indicated.
The pairs of fusion proteins were coexpressed in S. cerevisiae PJ69-4 and tested for interaction in a liquid culture
assay. A positive interaction resulted in a higher expression of
-galactosidase. Enzyme activity (shown in Miller units) was measured
as a function of chlorophenol red cleaved from CPRG
(chlorophenol-red- -D-galactopyranoside). For each
protein pair, three independent cotransformants were measured in
triplicate. Standard deviations based on differences between the three
cotransformants are indicated.
|
|
Taken together, these data demonstrate binding of Rep52 to Rep68 as
well as Rep68 to Rep78 and also indicate that Rep40 can
weakly bind
both Rep52 and
Rep78.
 |
DISCUSSION |
In this report we have described the protein-protein interactions
of AAV-2-encoded polypeptides which result in complexes between Rep
proteins and AAV-2 capsids. The same type of complex was formed
regardless of whether packageable DNA was present, suggesting that it
is not formed as the result of DNA packaging but rather constitutes an
intermediate required for encapsidation.
Several reports have previously described complexes of Rep proteins
with AAV-2 capsids (23, 31, 32, 46). However, they have been
primarily interpreted based on the MVMp paradigm described by Cotmore
and Tattersall (8), as a covalent linkage of Rep78 or Rep68
to the 5' terminus of the genome formed during the terminal resolution
reaction and preserved at the outside of the capsid after DNA packaging
has been completed (31, 32). A functional role for this type
of complex has been discussed and linked to the nuclear uptake of
parvovirus genomes during an infection or to the release of assembled
virus from the cell (8, 31, 32). Our interpretation suggests
a role for Rep-VP complexes in the DNA packaging process, in particular
at the initiation step during which the viral DNA must interact with
the parvovirus capsid. A role in DNA packaging has also been favored by
Cotmore and Tattersall (8); however, such a role would
involve a DNA-independent protein-protein interaction between
structural and nonstructural proteins, which the authors did not
observe. Here, we have presented several lines of evidence
demonstrating that such protein-protein interactions do indeed occur
and that they result in capsids displaying Rep proteins on the outside
of the viral shell. We have demonstrated this by coimmunoprecipitating
capsids with four different anti-Rep antisera. Similarly, Rep proteins
could be coprecipitated using three different anti-VP antisera but only
when capsid proteins were coexpressed. We have also isolated Rep
proteins by immunoaffinity chromatography on a matrix bound by MAb A20,
which recognizes assembled capsids (data not shown). In addition, the
small Rep proteins, which do not show sequence-specific DNA binding
(21), can form complexes with VP, further suggesting that
DNA is not involved in the initial complex formation. Analysis of Rep
mutants showed that sequences near or within the ATP-binding domain are required for this interaction. Several Rep mutants showed strongly reduced or no interaction with capsids, emphasizing the specificity of
the Rep-capsid associations. Finally, we could also detect a weak
interaction of Rep78 and Rep52 with VP proteins by using the yeast
two-hybrid system. A DNase-resistant complex of Rep proteins with
recombinant and wild-type AAV-2 virions has also been observed by Kube
et al. (23), who suggested a relationship between the
AAV-2-mediated influence on cell proliferation and the
capsid-associated Rep proteins. The authors observed that the
association of Rep proteins with the capsid surface is sensitive to
repeated CsCl centrifugation, i.e., to high salt concentrations, which
is in line with our own experience (data not shown). Additionally, an
indirect piece of evidence supporting a DNA-independent interaction of
Rep proteins with AAV-2 capsids is suggested by the strong influence
that the Rep proteins have on the intranuclear localization of
assembled empty capsids in HeLa cells (45).
At this stage the mechanism by which protein-protein interactions can
result in stable Rep-virion complexes is still unclear. Rep-VP
interactions can occur prior to assembly of the capsid proteins into
capsids. This is demonstrated by coimmunoprecipitation of VP proteins
with anti-Rep antibodies from sucrose gradient fractions sedimenting
below 20S, by coimmunoprecipitation of individually expressed capsid
proteins which have a strongly reduced capsid forming capacity
(38), and by the two-hybrid system in which the capsid
proteins are fused to protein domains and are therefore prevented from
forming capsids. That this interaction with nonassembled VP proteins
plays an important role in Rep-capsid complex formation is demonstrated
by the fact that coexpression of Rep and VP proteins leads to a much
more efficient complex formation than the mere association of Rep
proteins with capsids in vitro. Complex formation in vitro may be less
efficient for several reasons. The actual protein concentrations in the
nucleus and the availability of chaperones would certainly be different
during coexpression in vivo compared to coincubation in vitro, although
the amounts of Rep and VP proteins in the extracts were the same.
Nonetheless, the strikingly higher stability of complexes formed after
coexpression, compared to that after coincubation, strongly suggests
that protein-protein interactions during the assembly process are
important for the formation of this type of Rep-capsid complex.
The composition of the Rep-capsid complexes, as determined by
immunoprecipitation with different VP antibodies in the presence and
absence of AAV-2 DNA, suggests an abundance of Rep52, slightly less
Rep78, and a small amount of Rep68 associated with the capsid. In some
experiments, we could also detect traces of Rep40. Since all Rep
proteins are able to form such complexes when individually expressed
with capsid proteins, one would expect that they are represented in the
capsids according to their expression levels. Rep78 is normally
expressed at equal or higher levels than Rep52 in coinfection
experiments, yet the capsids precipitated in RIPA buffer always showed
a higher content of Rep52 than of Rep78. That these ratios are not
immunoprecipitation artefacts is supported by the quantitation of Rep
and VP proteins in sucrose gradient fractions without any precipitation
(Table 1). The determined ratios suggest a Rep78/VP2 ratio of about 1 and a slightly higher ratio of 2 to 4 for Rep52/VP2. However, an exact
determination of the Rep/VP stoichiometry in these complexes would
require a purification of the complexes. Precipitations performed in
buffer A (without detergents) gave much higher recoveries of Rep78,
suggesting a difference in the binding stabilities of Rep78 and Rep52
to the capsid. Since Rep-Rep interactions are unstable in RIPA buffer, the additional amounts of Rep78 (and Rep68) recovered by
immunoprecipitation in buffer A could thus result from Rep-Rep
interactions in addition to the detergent-stable complexes of Rep52,
Rep78, and Rep68 with the capsid. The low levels of Rep40 in the
Rep-capsid complexes is difficult to interpret, especially as capsids
were very efficiently coprecipitated with Rep antisera when Rep40 was
overexpressed together with the VP proteins. In infection experiments
and after transfection of pDG, however, expression levels of Rep40 were variable, but altogether low, making it difficult to judge whether the
low recovery in these experiments was due to the low protein concentration or rather to a lower stability of Rep40 in the complex. In several cosedimentation experiments, a polypeptide migrating slightly faster than Rep40 was observed at 60S. It remains to be
determined whether this protein represents a modified form of Rep40 or
a degradation product of one of the Rep proteins.
A problem that all viruses must solve is how to specifically package
their genome. Current concepts for the solution of this problem
postulate a specific interaction of a part of the genome, i.e., the
packaging sequence, with components of the packaging apparatus and
capsid. For the autonomous parvoviruses, a specific interaction of the
3' hairpin structure of MVM with the capsid (43) and an
interaction of a 3'-terminal fragment of the Aleutian mink disease
virus with VP1 (44) have been demonstrated. In contrast, a
direct interaction of AAV-2 ITRs, which are necessary and sufficient
for AAV-2 genome encapsidation, with free capsid proteins or capsids
produced in the absence of Rep proteins could not be demonstrated.
Alternatively, the required specific association of AAV-2 DNA with the
capsids could be achieved through Rep78 or Rep68 binding to the AAV-2
ITRs (20), followed by interaction with the capsid. We can
imagine two mechanisms by which this could be accomplished (Fig.
9). The large Rep proteins bound to the AAV-2 DNA could (i) become directly incorporated into the capsid during
capsid assembly or (ii) associate with capsids via interactions with
the small and large Rep proteins already incorporated into the capsids.
The fact that AAV-2 DNA packaging can be reconstituted in cell-free
extracts (9, 47) tends to favor the second mechanism, because capsid assembly in such cell-free systems is inefficient (38). A preencapsidation complex, as postulated by this
model, could also explain how the packaging of AAV-2 DNA genomes
engaged in DNA replication or mRNA synthesis is avoided. Specific
interactions of the Rep proteins covalently linked to the 5' end of the
genome with the preencapsidation complex could selectively sequester these molecules for DNA packaging. A question of future interest will
concern the mechanism by which the virus avoids the initiation of
packaging of multiple genomes and whether this is regulated by the
number of Rep molecules anchored to the capsid surface. The results and
the model presented here provide a basis for the analysis of these
questions and a better understanding of the parvovirus DNA packaging
process.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 9.
Working hypothesis for the specific binding of AAV-2 DNA
to capsids based on Rep-capsid complexes as described in this report.
(I) The association of Rep proteins with nonassembled capsid proteins
would allow the binding of a Rep-bound single-stranded AAV genome to
the capsid in a synchronous process. (II) In an alternative two-step
process, the Rep-capsid complexes are formed first and are subsequently
bound by the Rep-tagged packageable DNA to initiate the packaging
process. Both processes involve Rep-VP, Rep-capsid, Rep-Rep, and
Rep-DNA interactions.
|
|
 |
ACKNOWLEDGMENTS |
We thank Dirk Grimm for excellent assistance in the preparation
of pDG
VP and for critical reading of the manuscript. We are also
grateful to Jean-Claude Jauniaux and Celina Cziepluch for technical and
theoretical assistance in use of the yeast two-hybrid system.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Deutsches
Krebsforschungszentrum, Forschungsschwerpunkt Angewandte
Tumorvirologie, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany.
Phone: 49-6221-424978. Fax: 49-6221-424962. E-mail:
J.Kleinschmidt{at}dkfz-heidelberg.de.
Present address: Institut für Infektionsmedizin, Abteilung
Virologie, Freie Universität Berlin, D-12203 Berlin, Germany.
 |
REFERENCES |
| 1.
|
Beaton, A.,
P. Palumbo, and K. I. Berns.
1989.
Expression from the adeno-associated virus p5 and p19 promoters is negatively regulated in trans by the Rep protein.
J. Virol.
63:4450-4454[Abstract/Free Full Text].
|
| 2.
|
Berns, K. I.
1990.
Parvovirus replication.
Microbiol. Rev.
54:316-329[Abstract/Free Full Text].
|
| 3.
|
Berns, K. I., and R. A. Bohensky.
1987.
Adeno-associated viruses: an update.
Advances virus res.
32:243-305.
|
| 4.
|
Buller, R. M., and J. A. Rose.
1978.
Characterization of adenovirus-associated virus-induced polypeptides in KB cells.
J. Virol.
25:331-338[Abstract/Free Full Text].
|
| 5.
|
Chartier, C.,
E. Degryse,
M. Gantzer,
A. Dieterle,
A. Pavirani, and M. Mehtali.
1996.
Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli.
J. Virol.
70:4805-4810[Abstract].
|
| 6.
|
Chejanovsky, N., and B. J. Carter.
1989.
Mutagenesis of an AUG codon in the adeno-associated virus rep gene: effects on viral DNA replication.
Virology
173:120-128[Medline].
|
| 7.
|
Chen, C., and H. Okayama.
1987.
High-efficiency transformation of mammalian cells by plasmid DNA.
Mol. Cell. Biol.
7:2745-2752[Abstract/Free Full Text].
|
| 8.
|
Cotmore, S. F., and P. Tattersall.
1989.
A genome-linked copy of the NS-1 polypeptide is located on the outside of infectious parvovirus particles.
J. Virol.
63:3902-3911[Abstract/Free Full Text].
|
| 9.
|
Ding, L.,
S. Lu, and N. C. Munshi.
1997.
In vitro packaging of an infectious recombinant adeno-associated virus 2.
Gene Ther.
4:1167-1172[Medline].
|
| 10.
|
Gietz, R. D.,
R. H. Schiestl,
A. R. Willems, and R. A. Woods.
1995.
Studies on the transformation of intact yeast cells by the LiAc/SS- DNA/PEG procedure.
Yeast
11:355-360[Medline].
|
| 11.
|
Grimm, D.,
A. Kern,
K. Rittner, and J. A. Kleinschmidt.
1998.
Novel tools for the production and purification of recombinant AAV vectors.
Hum. Gene Ther.
9:2745-2760[Medline].
|
| 12.
|
Harlow, E., and D. Lane.
1988.
Antibodies: a laboratory manual.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 13.
|
Heilbronn, R.,
A. Burkle,
S. Stephan, and H. zur Hausen.
1990.
The adeno-associated virus rep gene suppresses herpes simplex virus-induced DNA amplification.
J. Virol.
64:3012-3018[Abstract/Free Full Text].
|
| 14.
|
Hermonat, P. L.,
M. A. Labow,
R. Wright,
K. I. Berns, and N. Muzyczka.
1984.
Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants.
J. Virol.
51:329-339[Abstract/Free Full Text].
|
| 15.
|
Holscher, C.,
J. A. Kleinschmidt, and A. Burkle.
1995.
High-level expression of adeno-associated virus (AAV) Rep78 or Rep68 protein is sufficient for infectious-particle formation by a Rep-negative AAV mutant.
J. Virol.
69:6880-6885[Abstract].
|
| 16.
|
Horer, M.
1996.
Ph.D Thesis.
Ruprecht-Karls-Universität, HeidelbergHeidelberg, Germany.
|
| 17.
|
Horer, M.,
S. Weger,
K. Butz,
F. Hoppe-Seyler,
C. Geisen, and J. A. Kleinschmidt.
1995.
Mutational analysis of adeno-associated virus Rep protein-mediated inhibition of heterologous and homologous promoters.
J. Virol.
69:5485-5496[Abstract].
|
| 18.
|
Hunter, L. A., and R. J. Samulski.
1992.
Colocalization of adeno-associated virus Rep and capsid proteins in the nuclei of infected cells.
J. Virol.
66:317-324[Abstract/Free Full Text].
|
| 19.
|
Im, D. S., and N. Muzyczka.
1990.
The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity.
Cell
61:447-457[Medline].
|
| 20.
|
Im, D. S., and N. Muzyczka.
1989.
Factors that bind to adeno-associated virus terminal repeats.
J. Virol.
63:3095-3104[Abstract/Free Full Text].
|
| 21.
|
Im, D. S., and N. Muzyczka.
1992.
Partial purification of adeno-associated virus Rep78, Rep52, and Rep40 and their biochemical characterization.
J. Virol.
66:1119-1128[Abstract/Free Full Text].
|
| 22.
|
James, P.,
J. Halladay, and E. A. Craig.
1996.
Genomic libraries and a host strain designed for highly efficient two-hybrid selection in yeast.
Genetics
144:1425-1436[Abstract].
|
| 23.
|
Kube, D. M.,
S. Ponnazhagan, and A. Srivastava.
1997.
Encapsidation of adeno-associated virus type 2 Rep proteins in wild-type and recombinant progeny virions: Rep-mediated growth inhibition of primary human cells.
J. Virol.
71:7361-7371[Abstract].
|
| 24.
|
Kyostio, S. R.,
R. A. Owens,
M. D. Weitzman,
B. A. Antoni,
N. Chejanovsky, and B. J. Carter.
1994.
Analysis of adeno-associated virus (AAV) wild-type and mutant Rep proteins for their abilities to negatively regulate AAV p5 and p19 mRNA levels.
J. Virol.
68:2947-2957[Abstract/Free Full Text].
|
| 25.
|
McCarty, D. M.,
T. H. Ni, and N. Muzyczka.
1992.
Analysis of mutations in adeno-associated virus Rep protein in vivo and in vitro.
J. Virol.
66:4050-4057[Abstract/Free Full Text].
|
| 26.
|
McLaughlin, S. K.,
P. Collis,
P. L. Hermonat, and N. Muzyczka.
1988.
Adeno-associated virus general transduction vectors: analysis of proviral structures.
J. Virol.
62:1963-1973[Abstract/Free Full Text].
|
| 27.
|
Muller, D. E., and G. Siegl.
1983.
Maturation of parvovirus LuIII in a subcellular system. II. Isolation and characterization of nucleoprotein intermediates.
J. Gen. Virol.
64:1055-1067[Abstract/Free Full Text].
|
| 28.
|
Muzyczka, N.
1992.
Use of adeno-associated virus as a general transduction vector for mammalian cells.
Curr. Top. Microbiol. Immunol.
158:97-129[Medline].
|
| 29.
|
Myers, M. W., and B. J. Carter.
1980.
Assembly of adeno-associated virus.
Virology
102:71-82[Medline].
|
| 30.
|
Pereira, D. J.,
D. M. McCarty, and N. Muzyczka.
1997.
The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection.
J. Virol.
71:1079-1088[Abstract].
|
| 31.
|
Prasad, K. M., and J. P. Trempe.
1995.
The adeno-associated virus Rep78 protein is covalently linked to viral DNA in a preformed virion.
Virology
214:360-370[Medline].
|
| 32.
|
Prasad, K. M.,
C. Zhou, and J. P. Trempe.
1997.
Characterization of the Rep78/adeno-associated virus complex.
Virology
229:183-192[Medline].
|
| 33.
|
Rose, J. A.,
J. K. Maizel,
J. K. Inman, and A. J. Shatkin.
1971.
Structural proteins of adeno-associated viruses.
J. Virol.
8:766-770[Abstract/Free Full Text].
|
| 34.
|
Ruffing, M.,
H. Zentgraf, and J. A. Kleinschmidt.
1992.
Assembly of viruslike particles by recombinant structural proteins of adeno-associated virus type 2 in insect cells.
J. Virol.
66:6922-6930[Abstract/Free Full Text].
|
| 35.
|
Samulski, R. J.,
L. S. Chang, and T. Shenk.
1989.
Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression.
J. Virol.
63:3822-3828[Abstract/Free Full Text].
|
| 36.
|
Schneider, S.,
M. Buchert, and C. M. Hovens.
1996.
An in vitro assay of beta-galactosidase from yeast.
Biotechniques
20:960-962[Medline].
|
| 37.
|
Smith, R. H., and R. M. Kotin.
1998.
The Rep52 gene product of adeno-associated virus is a DNA helicase with 3'-to-5' polarity.
J. Virol.
72:4874-4881[Abstract/Free Full Text].
|
| 38.
|
Steinbach, S.,
A. Wistuba,
T. Bock, and J. A. Kleinschmidt.
1997.
Assembly of adeno-associated virus type 2 capsids in vitro.
J. Gen. Virol.
78:1453-1462[Abstract].
|
| 39.
|
Thomas, J. O., and R. D. Kornberg.
1975.
An octamer of histones in chromatin and free in solution.
Proc. Natl. Acad. Sci. USA
72:2626-2630[Abstract/Free Full Text].
|
| 40.
|
Tratschin, J. D.,
I. L. Miller, and B. J. Carter.
1984.
Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function.
J. Virol.
51:611-619[Abstract/Free Full Text].
|
| 41.
|
Tratschin, J. D.,
J. Tal, and B. J. Carter.
1986.
Negative and positive regulation in trans of gene expression from adeno-associated virus vectors in mammalian cells by a viral rep gene product.
Mol. Cell. Biol.
6:2884-2894[Abstract/Free Full Text].
|
| 42.
|
Weger, S.,
A. Wistuba,
D. Grimm, and J. A. Kleinschmidt.
1997.
Control of adeno-associated virus type 2 cap gene expression: relative influence of helper virus, terminal repeats, and Rep proteins.
J. Virol.
71:8437-8447[Abstract].
|
| 43.
|
Willwand, K., and B. Hirt.
1991.
The minute virus of mice capsid specifically recognizes the 3' hairpin structure of the viral replicative-form DNA: mapping of the binding site by hydroxyl radical footprinting.
J. Virol.
65:4629-4635[Abstract/Free Full Text].
|
| 44.
|
Willwand, K., and O. R. Kaaden.
1988.
Capsid protein VP1 (p85) of Aleutian disease virus is a major DNA-binding protein.
Virology
166:52-57[Medline].
|
| 45.
|
Wistuba, A.,
A. Kern,
S. Weger,
D. Grimm, and J. A. Kleinschmidt.
1997.
Subcellular compartmentalization of adeno-associated virus type 2 assembly.
J. Virol.
71:1341-1352[Abstract].
|
| 46.
|
Wistuba, A.,
S. Weger,
A. Kern, and J. A. Kleinschmidt.
1995.
Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins.
J. Virol.
69:5311-5319[Abstract].
|
| 47.
|
Zhou, X., and N. Muzyczka.
1998.
In vitro packaging of adeno-associated virus DNA.
J. Virol.
72:3241-3247[Abstract/Free Full Text].
|
| 48.
|
Zolotukhin, S.,
M. Potter,
W. W. Hauswirth,
J. Guy, and N. Muzyczka.
1996.
A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells.
J. Virol.
70:4646-4654[Abstract].
|
Journal of Virology, November 1999, p. 8989-8998, Vol. 73, No. 11
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Goehringer, C., Rutschow, D., Bauer, R., Schinkel, S., Weichenhan, D., Bekeredjian, R., Straub, V., Kleinschmidt, J. A., Katus, H. A., Muller, O. J.
(2009). Prevention of cardiomyopathy in {delta}-sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors. Cardiovasc Res
82: 404-410
[Abstract]
[Full Text]
-
Nash, K., Chen, W., Salganik, M., Muzyczka, N.
(2009). Identification of Cellular Proteins That Interact with the Adeno-Associated Virus Rep Protein. J. Virol.
83: 454-469
[Abstract]
[Full Text]
-
Sonntag, F., Bleker, S., Leuchs, B., Fischer, R., Kleinschmidt, J. A.
(2006). Adeno-Associated Virus Type 2 Capsids with Externalized VP1/VP2 Trafficking Domains Are Generated prior to Passage through the Cytoplasm and Are Maintained until Uncoating Occurs in the Nucleus. J. Virol.
80: 11040-11054
[Abstract]
[Full Text]
-
Urabe, M., Nakakura, T., Xin, K.-Q., Obara, Y., Mizukami, H., Kume, A., Kotin, R. M., Ozawa, K.
(2006). Scalable Generation of High-Titer Recombinant Adeno-Associated Virus Type 5 in Insect Cells. J. Virol.
80: 1874-1885
[Abstract]
[Full Text]
-
Bleker, S., Pawlita, M., Kleinschmidt, J. A.
(2006). Impact of Capsid Conformation and Rep-Capsid Interactions on Adeno-Associated Virus Type 2 Genome Packaging. J. Virol.
80: 810-820
[Abstract]
[Full Text]
-
Bleker, S., Sonntag, F., Kleinschmidt, J. A.
(2005). Mutational Analysis of Narrow Pores at the Fivefold Symmetry Axes of Adeno-Associated Virus Type 2 Capsids Reveals a Dual Role in Genome Packaging and Activation of Phospholipase A2 Activity. J. Virol.
79: 2528-2540
[Abstract]
[Full Text]
-
Yoon-Robarts, M., Blouin, A. G., Bleker, S., Kleinschmidt, J. A., Aggarwal, A. K., Escalante, C. R., Linden, R. M.
(2004). Residues within the B' Motif Are Critical for DNA Binding by the Superfamily 3 Helicase Rep40 of Adeno-associated Virus Type 2. J. Biol. Chem.
279: 50472-50481
[Abstract]
[Full Text]
-
Warrington, K. H. Jr., Gorbatyuk, O. S., Harrison, J. K., Opie, S. R., Zolotukhin, S., Muzyczka, N.
(2004). Adeno-Associated Virus Type 2 VP2 Capsid Protein Is Nonessential and Can Tolerate Large Peptide Insertions at Its N Terminus. J. Virol.
78: 6595-6609
[Abstract]
[Full Text]
-
Kern, A., Schmidt, K., Leder, C., Muller, O. J., Wobus, C. E., Bettinger, K., Von der Lieth, C. W., King, J. A., Kleinschmidt, J. A.
(2003). Identification of a Heparin-Binding Motif on Adeno-Associated Virus Type 2 Capsids. J. Virol.
77: 11072-11081
[Abstract]
[Full Text]
-
Nony, P., Chadeuf, G., Tessier, J., Moullier, P., Salvetti, A.
(2002). Evidence for Packaging of rep-cap Sequences into Adeno-Associated Virus (AAV) Type 2 Capsids in the Absence of Inverted Terminal Repeats: a Model for Generation of rep-Positive AAV Particles. J. Virol.
77: 776-781
[Abstract]
[Full Text]
-
Schmidt, M., Chiorini, J. A., Afione, S., Kotin, R.
(2002). Adeno-Associated Virus Type 2 Rep78 Inhibition of PKA and PRKX: Fine Mapping and Analysis of Mechanism. J. Virol.
76: 1033-1042
[Abstract]
[Full Text]
-
Tessier, J., Chadeuf, G., Nony, P., Avet-Loiseau, H., Moullier, P., Salvetti, A.
(2001). Characterization of Adenovirus-Induced Inverted Terminal Repeat-Independent Amplification of Integrated Adeno-Associated Virus rep-cap Sequences. J. Virol.
75: 375-383
[Abstract]
[Full Text]
-
Schmidt, M., Afione, S., Kotin, R. M.
(2000). Adeno-Associated Virus Type 2 Rep78 Induces Apoptosis through Caspase Activation Independently of p53. J. Virol.
74: 9441-9450
[Abstract]
[Full Text]
-
Wobus, C. E., Hügle-Dörr, B., Girod, A., Petersen, G., Hallek, M., Kleinschmidt, J. A.
(2000). Monoclonal Antibodies against the Adeno-Associated Virus Type 2 (AAV-2) Capsid: Epitope Mapping and Identification of Capsid Domains Involved in AAV-2-Cell Interaction and Neutralization of AAV-2 Infection. J. Virol.
74: 9281-9293
[Abstract]
[Full Text]